Animal studies suggest that spinal muscular atrophy may result primarily from motor circuit dysfunction, not motor neuron or muscle cell dysfunction, as is commonly thought
posted on October 17, 2012 - 12:31pm
Results from a study in fruit flies conducted by scientists in the Motor Neuron Center at Columbia University Medical Center in New York suggest that spinal muscular atrophy (SMA) — commonly thought to be a disease of muscle-controlling nerve cells called motor neurons — instead results from the dysfunction of motor circuits (networks made up of different types of specialized neurons that...
Repligen soon will begin a first-ever human trial of a drug created specifically for spinal muscular atrophy; FDA grants fast track designation
posted on May 20, 2011 - 11:13am
In a historic first, biotech company Repligen Corp., of Waltham, Mass., has received approval from the U.S. Food and Drug Administration (FDA) to begin a phase 1 clinical trial of the experimental drug RG3039 for spinal muscular atrophy (SMA).
An ALS Therapy Development Institute Webcast summarizes research progress as of July 2009
posted on July 29, 2009 - 12:15pm
On July 16, 2009, the MDA-supported ALS Therapy Development Institute (ALS TDI) gave its quarterly research update in a Webcast that's now archived on the Institute's site and accessible to all who register. (See Research Update Q209.)